These data suggest that Calebin A may be able to act as an active multitargeting anticancer agent, and its action is partially mediated by the suppression of NF-κB and NF-κB-induced gene products in CRC-TME cells. This evidence concerns the gene NFKB1 and colorectal carcinoma.